You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD27 expressing Solid Tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,

Recruiting
  • Advanced or Metastatic Solid Tumors
  • CD40 ligand expressing MSLN-CAR T cells
  • +2 more
  • Beijing, Beijing, China
    Kaichao Feng
Jan 19, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma Trial in Beijing, Shanghai (IMM2902)

Recruiting
  • Advanced Solid Tumor
  • +3 more
  • Beijing, China
  • +1 more
Apr 6, 2023

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • 89Zr-TLX250
  • 177Lu-TLX250 and Peposertib
  • North Ryde, New South Wales, Australia
  • +4 more
May 22, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer Trial in Boston, Dallas, Fairfax (IMM2902)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

Kidney Cancer, Lymphomas, Positron Emission Tomography Trial in Shanghai ([18F]RCCB6 PET Imaging)

Recruiting
  • Kidney Cancer
  • +2 more
  • [18F]RCCB6 PET Imaging
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor

Not yet recruiting
  • HER2-expressing Advanced Solid Tumors
  • SHR-A1811 combined with Pyrotinib.
  • SHR-A1811 combined with other antitumor therapies
  • (no location specified)
Aug 28, 2023

Advanced Solid Tumor Trial (SHR-4602 for injection)

Not yet recruiting
  • Advanced Solid Tumor
  • SHR-4602 for injection
  • (no location specified)
Apr 6, 2023

Locally Advanced or Metastatic Solid Tumors Trial in Beijing (MSC-IFNa, Nab paclitaxel, Cyclophosphamide)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • MSC-IFNα
  • +3 more
  • Beijing, China
    Department of Biotherapeutic, Chinese PLA General Hospital
Jan 29, 2023

Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumors
  • TCR-T cells
  • +4 more
  • (no location specified)
Dec 12, 2022

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

HER2 Expressing or Mutated Advanced Malignant Solid Tumors Trial in China (GQ1005)

Recruiting
  • HER2 Expressing or Mutated Advanced Malignant Solid Tumors
  • Beijing, Beijing, China
  • +19 more
Nov 23, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +3 more
  • San Antonio, Texas
  • +1 more
Aug 22, 2022

Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • CD70 CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Advanced Solid Tumors Trial in Shanghai, Chengdu (SHR-A1811, Fluzoparib Capsule)

Enrolling by invitation
  • Advanced Solid Tumors
  • Shanghai, Shanghai, China
  • +1 more
Jun 28, 2022

Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

Withdrawn
  • Advanced Solid Tumor
  • TCRT-ESO-A2
  • (no location specified)
Aug 31, 2022

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Advanced Solid Tumors Trial in Guangzhou (MR001)

Not yet recruiting
  • Advanced Solid Tumors
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Nov 12, 2023

Advanced Solid Tumor Trial in Beijing (CD73 Antigen)

Recruiting
  • Advanced Solid Tumor
  • CD73 Antigen
  • Beijing, China
    Beijing Cancer Hospital
Jul 10, 2023

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Solid Tumor Trial (BS006 Injection)

Not yet recruiting
  • Solid Tumor
  • BS006 Injection
  • (no location specified)
Jul 3, 2023

Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)

Active, not recruiting
  • Solid Tumor
  • SYD985 + Niraparib
  • Antwerp, Belgium
  • +5 more
Jan 23, 2023

HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

Recruiting
  • HNSCC
  • +5 more
  • DP CD8 TIL
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jun 5, 2023